132 related articles for article (PubMed ID: 32211849)
1. LncRNA SDHAP1 confers paclitaxel resistance of ovarian cancer by regulating EIF4G2 expression via miR-4465.
Zhao H; Wang A; Zhang Z
J Biochem; 2020 Aug; 168(2):171-181. PubMed ID: 32211849
[TBL] [Abstract][Full Text] [Related]
2. Long non-coding RNA (LncRNA) SNHG7/ Eukaryotic translation initiation factor 4 gamma 2 (EIF4G2) involves in the malignant events of ovarian cancer cells with paclitaxel resistant.
Zhang J; Zhang R; Ye Y
Bioengineered; 2021 Dec; 12(2):10541-10552. PubMed ID: 34709112
[TBL] [Abstract][Full Text] [Related]
3. SNHG5 enhances Paclitaxel sensitivity of ovarian cancer cells through sponging miR-23a.
Lin H; Shen L; Lin Q; Dong C; Maswela B; Illahi GS; Wu X
Biomed Pharmacother; 2020 Mar; 123():109711. PubMed ID: 31884343
[TBL] [Abstract][Full Text] [Related]
4. UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis.
Wang J; Ye C; Liu J; Hu Y
Biochem Biophys Res Commun; 2018 Jul; 501(4):1034-1040. PubMed ID: 29777711
[TBL] [Abstract][Full Text] [Related]
5. Long non-coding RNA UCA1 promotes the progression of paclitaxel resistance in ovarian cancer by regulating the miR-654-5p/SIK2 axis.
Li ZY; Wang XL; Dang Y; Zhu XZ; Zhang YH; Cai BX; Zheng L
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):591-603. PubMed ID: 32016960
[TBL] [Abstract][Full Text] [Related]
6. lncRNA-PRLB Confers Paclitaxel Resistance of Ovarian Cancer Cells by Regulating RSF1/NF-κB Signaling Pathway.
Zhao Y; Hong L
Cancer Biother Radiopharm; 2021 Mar; 36(2):202-210. PubMed ID: 33156701
[No Abstract] [Full Text] [Related]
7. Long noncoding RNA CASC2 promotes paclitaxel resistance in breast cancer through regulation of miR-18a-5p/CDK19.
Zheng P; Dong L; Zhang B; Dai J; Zhang Y; Wang Y; Qin S
Histochem Cell Biol; 2019 Oct; 152(4):281-291. PubMed ID: 31352515
[TBL] [Abstract][Full Text] [Related]
8. KHDRBS3 promotes paclitaxel resistance and induces glycolysis through modulated MIR17HG/CLDN6 signaling in epithelial ovarian cancer.
Wu X; Qiu L; Feng H; Zhang H; Yu H; Du Y; Wu H; Zhu S; Ruan Y; Jiang H
Life Sci; 2022 Mar; 293():120328. PubMed ID: 35051418
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of lncRNA CCAT1 enhances sensitivity of paclitaxel in prostate cancer via regulating miR-24-3p and FSCN1.
Li X; Han X; Wei P; Yang J; Sun J
Cancer Biol Ther; 2020 May; 21(5):452-462. PubMed ID: 32089062
[TBL] [Abstract][Full Text] [Related]
10. Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer.
Huh JH; Kim TH; Kim K; Song JA; Jung YJ; Jeong JY; Lee MJ; Kim YK; Lee DH; An HJ
Br J Cancer; 2013 Jul; 109(2):452-61. PubMed ID: 23807165
[TBL] [Abstract][Full Text] [Related]
11. Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells.
Xu J; Wu J; Fu C; Teng F; Liu S; Dai C; Shen R; Jia X
J Cell Physiol; 2018 Jun; 233(6):5034-5043. PubMed ID: 29219179
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis.
Eoh KJ; Lee SH; Kim HJ; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
Biochem Biophys Res Commun; 2018 Mar; 497(2):513-520. PubMed ID: 29452092
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.
Jeong JY; Kang H; Kim TH; Kim G; Heo JH; Kwon AY; Kim S; Jung SG; An HJ
Cancer Lett; 2017 Feb; 386():168-178. PubMed ID: 27887917
[TBL] [Abstract][Full Text] [Related]
14. Linc00161 regulated the drug resistance of ovarian cancer by sponging microRNA-128 and modulating MAPK1.
Xu M; Zhou K; Wu Y; Wang L; Lu S
Mol Carcinog; 2019 Apr; 58(4):577-587. PubMed ID: 30556928
[TBL] [Abstract][Full Text] [Related]
15. Circular RNA circ-PVT1 contributes to paclitaxel resistance of gastric cancer cells through the regulation of ZEB1 expression by sponging miR-124-3p.
Liu YY; Zhang LY; Du WZ
Biosci Rep; 2019 Dec; 39(12):. PubMed ID: 31793989
[TBL] [Abstract][Full Text] [Related]
16. CircATL2 enhances paclitaxel resistance of ovarian cancer via impacting miR-506-3p/NFIB axis.
Ying H; Zhao R; Yu Q; Zhang K; Deng Q
Drug Dev Res; 2022 Apr; 83(2):512-524. PubMed ID: 34541682
[TBL] [Abstract][Full Text] [Related]
17. Ginsenoside 20(S)-Rg3 Prevents PKM2-Targeting miR-324-5p from H19 Sponging to Antagonize the Warburg Effect in Ovarian Cancer Cells.
Zheng X; Zhou Y; Chen W; Chen L; Lu J; He F; Li X; Zhao L
Cell Physiol Biochem; 2018; 51(3):1340-1353. PubMed ID: 30481782
[TBL] [Abstract][Full Text] [Related]
18. LncRNA HEIH Enhances Paclitaxel-Tolerance of Endometrial Cancer Cells via Activation of MAPK Signaling Pathway.
Guo JL; Tang T; Li JH; Yang YH; Zhang L; Quan Y
Pathol Oncol Res; 2020 Jul; 26(3):1757-1766. PubMed ID: 31650338
[TBL] [Abstract][Full Text] [Related]
19. Down-regulated expression of miR-134 contributes to paclitaxel resistance in human ovarian cancer cells.
Shuang T; Wang M; Shi C; Zhou Y; Wang D
FEBS Lett; 2015 Oct; 589(20 Pt B):3154-64. PubMed ID: 26363097
[TBL] [Abstract][Full Text] [Related]
20. miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6.
Zhu X; Li Y; Xie C; Yin X; Liu Y; Cao Y; Fang Y; Lin X; Xu Y; Xu W; Shen H; Wen J
Int J Cancer; 2014 Sep; 135(6):1286-96. PubMed ID: 24510775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]